Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease  

作　　者：Sha Sha Lina Ren Xiaona Xing Wanshu Guo Yan Wang Ying Li Yunpeng Cao Le Qu 

机构地区：[1]Department of Geriatrics,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,China [2]Department of Neurology,Shenzhen Luohu People’s Hospital,The Third Affiliated Hospital of Shenzhen University,Shenzhen,Guangdong Province,China [3]Department of Neurology,People’s Hospital of Liaoning Province,Shenyang,Liaoning Province,China [4]Department of Neurology,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,China [5]Department of Dermatology,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,China

出　　处：《Neural Regeneration Research》2026年第2期577-587,共11页中国神经再生研究(英文版)

基　　金：supported by the Nature Science Foundation of Liaoning Province,Nos.2022-MS-211,2021-MS-064,and 2024-MS-048(all to YC).

摘　　要：Alzheimer’s disease,a devastating neurodegenerative disorder,is characterized by progressive cognitive decline,primarily due to amyloid-beta protein deposition and tau protein phosphorylation.Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease.Conventional drugs,such as donepezil,can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline.Currently,active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models,attracting considerable attention.However,the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab.This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins.Furthermore,it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects.Although some antibodies have shown promise in patients with mild Alzheimer’s disease,substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease.

关 键 词：Alzheimer’s disease amyloid deposits AMYLOID-BETA antibody cognitive dysfunction dementia IMMUNOTHERAPY OLIGOMER preventive immunization tau hyperphosphorylation 

分 类 号：R749.1[医药卫生—神经病学与精神病学]